TICKERNERD
Menu
SXTPSXTPHealthcare · Biotechnology

SXTP Stock Forecast: 60 Degrees Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$0.88
−1.58% on the day

The 2 Wall Street analysts covering 60 Degrees Pharmaceuticals, Inc. hold a median 12-month price target of $3.7 — +322.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Oct 2026 — in the lower half.

Market cap
$3.1M
Ticker Nerd rank
41/ 100
Median analyst target
$3.70
Analysts covering
2
Revenue$208K+106.0% y/y
Operating income−$2.3M
Net income−$2.3M
Free cash flow−$2.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
−15.8%
YTD
−56.9%
1Y
−85.2%
From 52W high
−85.2%
From 52W low
+5.9%
$0.83
$5.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SXTP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 60 Degrees Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
41/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Revisions
90
Growth
65
Volatility
57
Value
33
Accruals
28
Issuance
25
Quality
17
Momentum
7

Size (97): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SXTP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SXTP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26SXTPHigh $3.70Median $3.70Low $3.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $3.70Median $3.70High $3.70

The green dot is the last close — the median target sits +322.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 May 2026Ascendiant CapitalMaintainsBuy$4.20 → $3.70
20 May 2026HC Wainwright & Co.DowngradeNeutral—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
27 Jan 2026HC Wainwright & Co.MaintainsBuy—
28 Nov 2025Ascendiant CapitalMaintainsBuy—
14 Nov 2025HC Wainwright & Co.AssumesBuy$6.00
3 Sept 2025Ascendiant CapitalMaintainsBuy—
2 June 2025Ascendiant CapitalMaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
25 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
10 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
23 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
11 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
15 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
13 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
6 June 2024HC Wainwright & Co.ReiteratesNeutral—
3 Apr 2024HC Wainwright & Co.ReiteratesNeutral—
20 Oct 2023HC Wainwright & Co.InitiatesNeutral—
2 Oct 2023Ascendiant CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SXTP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

SXTP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, 60 Degrees Pharmaceuticals, Inc. returned −85.2% against +15.6% for the S&P 500, dividends included.

SXTP vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26SXTPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SXTP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

60 Degrees Pharmaceuticals, Inc. (SXTP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.7×

Cheaper than 46% of US stocks

Price / sales
2.5×

Cheaper than 45% of US stocks

Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
−1.4×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−32.5%

Higher than 8% of US stocks

Earnings growth (YoY)
106.0%

Higher than 84% of US stocks

Gross margin
27.3%

Higher than 30% of US stocks

Operating margin
−1092.4%

Higher than 5% of US stocks

Net margin
22.3%

Higher than 84% of US stocks

Returns & dividend
Return on equity
−332.9%

Higher than 5% of US stocks

Return on assets
−127.1%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

60 Degrees Pharmaceuticals, Inc. (SXTP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 60 Degrees Pharmaceuticals, Inc. has a market value of $3.1M and an enterprise value of $11.7M.

  • Revenue in the twelve months to 30 June 2026: $1.1M. The latest quarter shrank 32.5% year on year.

  • Net income over the same four quarters: −$8.1M, a −730.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$9.1M, after $81K of capital spending.

  • Shares outstanding: 2.7M.

  • Trailing P/E: 14.7×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • 60 Degrees Pharmaceuticals, Inc. employs 3 people — $370K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Oct 2026

Data provided by Twelve Data

Peers

SXTP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SXTP60 Degrees Pharmaceuticals, Inc.$3.1M41
GRIGRI Bio, Inc.$3.1M34
CMNDClearmind Medicine, Inc.$3.0M6
EOCNEocene Ltd.$3.2M21
APVOAptevo Therapeutics, Inc.$2.9M30
PPCBPropanc Biopharma, Inc.$2.8M52
ERNAErnexa Therapeutics, Inc.$3.4M37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 60 Degrees Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SXTP news & analysis

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

GlobeNewsWire · 6 Oct 2026neutral

60 Degrees Pharmaceuticals plans to conclude enrollment in its severe babesiosis study at 30 patients and proceed with unblinding; primary and secondary endpoint results are expected in January 2027. The company also plans to request a pre-sNDA meeting with the FDA that month.

Why it matters — The readout and planned FDA discussion will provide updates on clinical results and the company’s proposed regulatory pathway for tafenoquine in severe or treatment-refractory babesiosis.

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

GlobeNewsWire · 1 Oct 2026neutral

60 Degrees Pharmaceuticals announced that interim data from its clinical study of tafenoquine in severe babesiosis will be released on October 6, 2026. A Key Opinion Leader investor webinar will be held the same day, featuring babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

Why it matters — The upcoming interim data release and expert webinar represent a key upcoming clinical milestone for 60 Degrees Pharmaceuticals that SXTP watchers will want to follow.

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 3 Sept 2026neutral

60 Degrees Pharmaceuticals (Nasdaq: SXTP) will present on demand at the H.C. Wainwright 28th Annual Global Investment Conference beginning Sept. 11, and will hold one-on-one investor meetings Sept. 14–16 in New York.

Why it matters — A SXTP watcher would care because participation in the conference offers the company exposure to investors at a major industry event.

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

GlobeNewsWire · 14 Aug 2026positive

60 Degrees Pharmaceuticals reported its financial results for the second quarter of 2026, ended June 30, 2026. Net product revenues increased approximately 106% to approximately $208 thousand, up from approximately $101 thousand in the second quarter of 2025.

Why it matters — A SXTP watcher would care because the company reported a substantial increase in net product revenues for the quarter, indicating improved commercial performance for its vector-borne disease medicines.

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewsWire · 30 July 2026neutral

60 Degrees Pharmaceuticals announced a private placement, issuing 574,713 shares of common stock (or pre-funded warrants) along with series A and short-term series B warrants at a purchase price of $1.74 per share, with the warrants exercisable at $1.49 per share upon issuance.

Why it matters — SXTP watchers would care because this private placement represents a capital raise that could dilute existing shareholders while potentially providing the company with additional funding for its vector-borne disease drug pipeline.

FAQ

Frequently asked questions about SXTP stock

What is the SXTP stock price forecast for 2026-2027?

The 2 Wall Street analysts covering 60 Degrees Pharmaceuticals, Inc. have a median 12-month price target of $3.7, with estimates ranging from $3.7 to $3.7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SXTP stock a buy right now?

Of the 2 analysts covering 60 Degrees Pharmaceuticals, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 60 Degrees Pharmaceuticals, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SXTP?

As at 22 Oct 2026, 60 Degrees Pharmaceuticals, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will SXTP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +322.4% from the last close, and Ticker Nerd's factor model ranks 60 Degrees Pharmaceuticals, Inc. 41 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SXTP stock forecast for 2030?

No analyst covering 60 Degrees Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.7 to $3.7 over the next 12 months.

How has SXTP stock performed over the past year?

60 Degrees Pharmaceuticals, Inc. returned -85.2% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 60 Degrees Pharmaceuticals, Inc. do?

60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases.

What is the latest news on SXTP?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA". 60 Degrees Pharmaceuticals plans to conclude enrollment in its severe babesiosis study at 30 patients and proceed with unblinding; primary and secondary endpoint results are expected in January 2027. The company also plans to request a pre-sNDA meeting with the FDA that month.

Company

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections. The company works across areas such as malaria, babesiosis, respiratory infections, and dengue, reflecting a research strategy aimed at diseases with significant unmet medical need. 60 Degrees Pharmaceuticals Inc. serves as a niche biotechnology player in the healthcare market, combining product commercialization with ongoing clinical development. Headquartered in Washington, D.C., the company also maintains operations linked to research and collaboration in Australia.

CEO Dr. Geoffrey Stuart Dow Ph.D. · 3 employees · United States · https://www.60degreespharma.com